CERo Therapeutics Holdings, Inc. - Common Stock CERO 深 滬
交易中 09-09 11:57:41 美东时间
4.68
0.000
0.00%
華盛通- 最 高4.91
- 今 開4.54
- 成交量 11.15万股
- 最 低 4.54
- 昨 收 4.68
- 總市值 180.69万
- 52周最高 895.40
- 市盈率 靜 --
- 換手率 28.87%
- 52周最低 4.2701
- 委 比 -97.74%
- 總股本 38.61万
- 歷史最高 24760.00
- 量 比 0.31
- 振 幅 7.91%
- 歷史最低 4.54
- 每 手 1
- 風險率 116.48%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Top 3 Health Care Stocks You'll Regret Missing In Q3
The most oversold stocks in the health care sector presents an opportunity to b...
今天 21:12
CERo Therapeutics Secures U.S. And Japanese Patents For CER-1236
Additional patent granted from the Japanese patent office now results in 20 granted patents and allowed applications covering the compound and its underlying technologySOUTH SAN FRANSCISCO, Calif., Sept. 09, 2025 (GLOBE
今天 20:18
CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041
CERo Therapeutics Holdings, Inc.宣布，美国专利和商标局允许其申请19/019,111，将为CER-1236提供至2041年的保护。日本专利的获得使国际专利总数达18项，另2项申请中。 CEO称知识产权强劲，临床试验进展顺利。
今天 12:15
CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia
CERo Therapeutics Holdings, Inc. announced that it has administered the second dose to the second patient in the first cohort of its Phase 1 CER-1236 clinical trial for acute myeloid leukemia (AML). The Institutional Review Board (IRB) approved a multi-dose intensification after reviewing initial pharmacokinetic data, effectively doubling the cell product infusion. The company aims to evaluate the safety and feasibility of multiple infusions and ...
09-08 12:45
美股大行评级 | 潜在涨幅65.5%！花旗上调Braze目标价至52美元，维持"买入"评级
今日重点评级关注：花旗：维持Braze"买入"评级，目标价从50美元升至52美元；花旗：维持Docusign"买入"评级，目标价从115美元升至120美元
09-08 10:23
D. Boral Capital Maintains Buy on CERo Therapeutics Hldgs, Maintains $30 Price Target
D. Boral Capital analyst Jason Kolbert maintains CERo Therapeutics Hldgs (NASDAQ:CERO) with a Buy and maintains $30 price target.
09-06 02:11
CERo Therapeutics Gains Fast Track for AML Drug
CERo Therapeutics Holdings ( ($CERO) ) has issued an update. On September 5, 20...
09-05 20:57
Why Docusign Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
Shares of Docusign Inc (NASDAQ:DOCU) rose sharply in pre-market trading after t...
09-05 17:20
CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML)
CERo Therapeutics Holdings, Inc. announced that the U.S. FDA has granted Fast Track Designation to its lead investigational compound, CER-1236, for Acute Myeloid Leukemia (AML). This designation, in addition to the existing Orphan Drug Designation, aims to accelerate the development and review of therapies for serious or life-threatening conditions with unmet medical needs. The Company expects this to reduce the potential time to market and provi...
09-05 12:00
CERo Therapeutics Faces Nasdaq Delisting Risk
The latest announcement is out from CERo Therapeutics Holdings ( ($CERO) ). On ...
09-05 04:38
